Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if using a subject's baseline frailty score to
guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd
lite).
Phase:
Phase 2
Details
Lead Sponsor:
Attaya Suvannasankha
Collaborators:
Indiana Institute for Medical Research Janssen Scientific Affairs, LLC